The purpose of the assessment is to evaluate sorafenib Nexavar® and its use as a treatment of thyroid carcinoma
Final version of the assessment was published in March 2015
Below is the documentation provided by the Joint Assessment authoring team:
Sorafenib for the treatment of thyroid carcinoma_Rapid REA_Final_Mar 2015_0
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.
